NDT Advance Access originally published online on July 27, 2004
Nephrology Dialysis Transplantation 2004 19(10):2526-2531; doi:10.1093/ndt/gfh272
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nephrol Dial Transplant Vol. 19 No. 10 © ERA-EDTA 2004; all rights reserved
Original Article
Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients
1 University of Tübingen, Department of Internal Medicine, Section for Nephrology and Hypertension and 2 University of Tübingen, Department of Radiology, Tübingen, Germany
Correspondence and offprint requests to: Christiane M. Erley, MD, St Joseph-Krankenhaus, Department of Medicine II, Bäumerplan 24, D-12101 Berlin, Germany. Email: christiane.erley{at}sjk.de
Background. To determine whether gadolinium-based contrast media (CM) could be used safely for angiographies in patients with renal dysfunction we investigated renal function after gadobutrol exposure and compared the results with standard iodinated CM (iohexol) in a randomized clinical study.
Methods. Twenty-one patients (aged 67±11 years, nine female and 12 male) with severely impaired renal function [mean serum creatinine 3.2±1.3 mg/dl, mean glomerular filtration rate (GFR) 31±16 ml/min/1.73 m2] who needed to have angiography because of severe peripheral vascular disease, renal artery stenosis or aortic aneurysms were randomized to receive in a blinded manner either gadobutrol (Gadovist® 1.0 mmol/ml) or iohexol (Omnipaque® 350) as contrast agents. GFR was measured by CM clearance (Renalyzer®) at baseline and 48 h after CM administration. The primary end point was the mean change of GFR from baseline at 48 h, the secondary one the incidence of CM-induced acute renal failure, defined as a decrease in GFR of >50% from baseline within 48 h of CM administration.
Results. In the gadobutrol group (n = 10) we observed a statistically significant decrease in GFR of 10.6±13.8 ml/min/1.73 m2 within 48 h after CM administration (P<0.05, paired t test). The incidence of CM-induced ARF amounted to 50%. In comparison, the iohexol group (n = 11) also showed a statistically significant GFR reduction of 8.7±8.8 ml/min/1.73 m2 (P<0.05, paired t test), and of ARF by 45%. The percentile of differences of GFR decreases between the two groups was not significant (P = 0.70). No patient demonstrated other adverse effects of gadobutrol or iohexol administration, apart from GFR reduction. Despite the decline in GFR, no patient required haemodialysis in the 10 following days.
Conclusions. In our study, gadolinium-based angiography showed no benefit over iohexol angiography with respect to preventing GFR reduction in patients with severely impaired renal function.
Keywords: angiography; contrast media-induced nephropathy; contrast media plasma clearance; gadolinium; glomerular filtration rate; iohexol
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Schor-Bardach, D. C. Alsop, I. Pedrosa, S. A. Solazzo, X. Wang, R. P. Marquis, M. B. Atkins, M. Regan, S. Signoretti, R. E. Lenkinski, et al. Does Arterial Spin-labeling MR Imaging-measured Tumor Perfusion Correlate with Renal Cell Cancer Response to Antiangiogenic Therapy in a Mouse Model? Radiology, June 1, 2009; 251(3): 731 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Bridges, B. S. St. Amant, R. B. McNeil, J. G. Cernigliaro, J. P. Dwyer, and P. M. Fitzpatrick High-Dose Gadodiamide for Catheter Angiography and CT in Patients With Varying Degrees of Renal Insufficiency: Prevalence of Subsequent Nephrogenic Systemic Fibrosis and Decline in Renal Function Am. J. Roentgenol., June 1, 2009; 192(6): 1538 - 1543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ledneva, S. Karie, V. Launay-Vacher, N. Janus, and G. Deray Renal Safety of Gadolinium-based Contrast Media in Patients with Chronic Renal Insufficiency Radiology, March 1, 2009; 250(3): 618 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Perazella Current Status of Gadolinium Toxicity in Patients with Kidney Disease Clin. J. Am. Soc. Nephrol., February 1, 2009; 4(2): 461 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Weinreb Which Study When? Is Gadolinium-enhanced MR Imaging Safer than Iodine-enhanced CT? Radiology, October 1, 2008; 249(1): 3 - 8. [Full Text] [PDF]
|
|
|
|
|
|
B. Elmstahl, U. Nyman, P. Leander, K. Golman, C.-M. Chai, D. Grant, R. Doughty, R. Pehrson, J. Bjork, and T. Almen Iodixanol 320 Results in Better Renal Tolerance and Radiodensity than Do Gadolinium-based Contrast Media: Arteriography in Ischemic Porcine Kidneys Radiology, April 1, 2008; 247(1): 88 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Nyman, B. Elmstahl, and P. Leander Suggesting Gadolinium-based Contrast Media for CT in Azotemic Patients Is Not Based on Historical, Clinical, and Experimental Data Radiology, August 1, 2007; 244(2): 622 - 623. [Full Text] [PDF]
|
|
|
|
|
|
M. C. Heinrich, M. K. Kuhlmann, S. Kohlbacher, M. Scheer, A. Grgic, M. B. Heckmann, and M. Uder Cytotoxicity of Iodinated and Gadolinium-based Contrast Agents in Renal Tubular Cells at Angiographic Concentrations: In Vitro Study Radiology, December 19, 2006; (2006) 2422060245. [Abstract] [Full Text]
|
|
|
|
|
|
J. Becker, H. Thompson, M. Remy-Jardin, J. Remy, and P. Dequiedt Renal Safety of Gadolinium-based Contrast Agent for Ionizing Radiation Imaging. Radiology, July 1, 2006; 240(1): 301 - 302. [Full Text] [PDF]
|
|
|
|
|
|
B. M. Elicker, Y. S. Cypel, and J. C. Weinreb IV contrast administration for CT: a survey of practices for the screening and prevention of contrast nephropathy. Am. J. Roentgenol., June 1, 2006; 186(6): 1651 - 1658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ergun, K. Keven, I. Uruc, Y. Ekmekci, B. Canbakan, I. Erden, and O. Karatan The safety of gadolinium in patients with stage 3 and 4 renal failure Nephrol. Dial. Transplant., March 1, 2006; 21(3): 697 - 700. [Abstract] [Full Text] [PDF]
|
|